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E7 oncoproteins of mucosal high-risk human papil-
lomavirus type 16 and 18 (HPV16 and HPV18)
immortalize primary rodent cells and transform
them in collaboration with the activated ras, possibly
by interaction with retinoblastoma gene product RB
and its related p107. On the other hand, E7 of the
cutaneous epidermodysplasia verruciformis-associ-
ated HPV5 and HPV8 possess ras-collaborative trans-
formation but not immortalization activity. By using
polymerase chain reaction, we constructed chimeric
E7 from immortalizing HPV16 E7 and non-
immortalizing HPV5 E7, which have boundaries at
the 37/39th, 61/62th, or 79th codon of the HPV16
E7. These chimeric E7 were cloned into the expres-
sion vectors to examine their ras-collaboration and
immortalization activities. Chimeric E7 that con-
tained N-terminal 39 amino acid residues (R), 61R
and 79R of HPV16 E7, showed ras-collaboration
activity in primary rat embryo ®broblast and pri-
mary baby rat kidney (BRK) cells as ef®ciently as
HPV16 E7. Meanwhile, only the chimeric E7 con-
taining N-terminal 79R of HPV16 E7 was able to
immortalize primary BRK cells without second
oncogenes. Co-transfection of two chimeric E7
carrying HPV16 N-terminus and HPV16 C-terminus
induced immortalization of primary BRK cells.
These results suggest that (i) in addition to the
N-terminal RB-binding domain, the C-terminal
region of HPV16 E7 is essential for immortalization
of primary BRK cells, and (ii) two different
immortalization functions are present in the two
regions of HPV16 E7. By using a yeast two hybrid
system, we searched for the HeLa cDNA whose pro-
ducts can bind the C-terminal region of HPV16 E7.
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M
ore than 10 speci®c types of human papilloma-
viruses (HPV), including HPV16, 18, 31, 33, 35,
39, 45, 51, 52, 55, 56, 58, 59, 66, and 68, are
closely associated with genital cancers and thus
called mucosal or genital high-risk HPV (Lorincz
et al, 1992; Villa, 1997). The E6 and E7 open reading frames (ORF)
of high-risk HPV are considered to be transforming genes of HPV,
as they always persist in the HPV-related cancer cells (Schwarz et al,
1985; Choo and Pan, 1987) and the E6/E7 region under a strong
heterologous promoter induces immortalization of human
keratinocytes (Hawley-Nelson et al, 1989; Barbosa and Schlegel,
1989; Munger et al, 1989a). HPV16 E6 binds tumor suppressor
protein p53 and enhances its degradation in vitro (Scheffner et al,
1990; Werness et al, 1990). The E7 of high-risk types binds
retinoblastoma tumor suppressor (RB) and its related p107 proteins,
which form complexes with transcription factor E2F in the early
G1 phase of the cell cycle (Dyson et al, 1989; Munger et al, 1989b;
Arroyo et al, 1993; Davies et al, 1993). Complex formation of E7
with RB/p107 might result in an increased level of free,
transcriptionally active E2F in the late G1 phase, which might
then transactivate cellular proteins required for G1/S progression
(Nevins, 1992). Thus, interactions of E6 and E7 of genital high-risk
HPV with the cellular proteins are believed to be responsible for
immortalization and/or carcinogenic process of infected cells.
Immortalization of primary human cells can be induced by a
single introduction of HPV16 E7 but only with a low
ef®ciency (Halbert et al, 1991). It has been shown that only a
part of the clones in which both HPV16 E6 and E7 were
expressed was immortalized (Klingelhutz et al, 1994). The low
ef®ciency of immortalization of human cells by viral oncogenes
is considered to result from loss of telomeres during cell
division (Stamps et al, 1992), and re-activation of telomerase
might be required for immortalization of human cells, including
HPV16 E6/E7-expressing keratinocytes (Klingelhutz et al,
1994). Recently, HPV16 E6 but not E7 was reported to
activate telomerase (catalytic subunit of human telomerase:
hTERT) (Klingelhutz et al, 1996; Stoppler et al, 1997).
Moreover, a combination of hTERT and HPV16 E7 (or
inactivation of p16INK4a) as well as that of HPV16 E6 and E7
was shown to immortalize human mammary epithelial cells and
keratinocytes (Kiyono et al, 1998; McDougall and Klingelhutz,
1999). This suggests the important roles of the RB/p16
pathway and activation of telomerase in the process of HPV-
mediated immortalization of human cells.
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There are several proteins other than RB family members,
however, that have been reported to bind E7 of high-risk HPV (see
Zwerschke and Jansen-Durr, 2000 for review). It has also been
reported that E7 mutants of high-risk HPV were defective for
transformation despite their retention of RB binding (McIntyre
et al, 1993), and that HPV16 carrying RB-nonbinding E7 can still
immortalize human keratinocytes (Jewers et al, 1992; Davies et al,
1993). Thus, functions of HPV E7 other than RB/p107 binding
might have some roles in the process of immortalization and
malignant conversion of infected cells.
At least four cutaneous HPV types, HPV5, 8, 17, and 20, are
closely associated with the squamous cell carcinoma developed in
the skin lesion of epidermodysplasia verruciformis (EV) patients
(Orth, 1987). E7 oncoprotein of HPV5 and HPV8 can transform
primary rat cells collaboratively with the activated ras gene, but are
unable to immortalize primary baby rat kidney (BRK) cells
(Nishikawa et al, 1991; Yamashita et al, 1993) (Table I). Both of
the E7 of HPV 5 and HPV8 can bind RB, however, with lower
ef®ciency than HPV16 E7 (Yamashita et al, 1993). To determine
the subregion of HPV16 E7 that is required for transformation and
immortalization, chimeric E7 were constructed from immortalizing
HPV16 E7 and nonimmortalizing HPV5 E7. Here, we examined
ras collaboration and immortalization of chimeric E7, and found
that, unlike ras-collaborative transformation, immortalization of
primary BRK cells required both the N-terminal and the
C-terminal regions of HPV16 E7. Yeast two hybrid assay was
carried out to isolate cellular proteins that might interact with the
C-terminus of HPV16 E7.
MATERIALS AND METHODS
Cells Primary rat embryo ®broblast (REF) and primary BRK cells
were prepared from 15±16-d embryos and 3±5-d-old newborns of F344
rats, respectively, as described previously (Nishikawa et al, 1991;
Yamashita et al, 1993). Cells were cultured in Dulbecco's modi®ed
Eagle's medium (DME) supplemented with 5% fetal bovine serum (FBS),
40 mg per ml penicillin G and 30 mg per ml streptomycin.
Transfection Secondary culture of REF cells and primary BRK cells
in 10 cm dishes were transfected with 5.0±20.0 mg of plasmid DNA,
basically according to the calcium phosphate-coprecipitatoion technique
described by van der Eb and Graham (1975). Transfected cells were
exposed to 15% glycerol in HEPES buffer for 1 min, washed twice with
phosphate-buffered saline (PBS), and re-fed with DME with 5% FBS
and cultured for 3 h. Then, cells were detached and split into quarters
into the four fresh 10 cm dishes. Cells were cultured for 2±3 weeks in
G418 (350 mg per ml for REF cells and 150 mg per ml for BRK cells)
containing media. Transformation was detected by the characteristic
feature of colonies in cells transfected with E7 and pEJ6.6 (Nishikawa
et al, 1991; Yamashita et al, 1993). Immortalization assay was carried out
by generation and growing of G418-resistant colonies from E7-
transfected primary BRK cells (Yamashita et al, 1993).
Plasmids pcD2-Y (Chen and Okayama, 1987; Nishikawa et al, 1991)
is a SV40-based expression vector used in transformation and














HPV5/8 ± + ± + +
HPV16 + ++ + ++ ++
aYamashita et al, 1993.
bYamashita, unpublished data.
Figure 1. Alignments of HPV5 and HPV16 E7. Amino acid sequences deduced from nucleotide sequences of HPV5 and HPV16 E7 were aligned
to obtain maximum homology. Boxed amino acids are parts of the LXCXL stretch that is essential for RB binding. Vertical lines between the 36th and
37th, 61st and 62nd, and 79th and 80th amino acid residues on the HPV16 E7 are boundaries of the chimeric E7 constructed in this study.
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immortalization assay. pEJ6.6 carries a 6.6 kilobase (kb)-fragment of
activated c-Ha-ras (Shih and Weinberg, 1982). pGEM-16E7, pGEM-5E7
(Yamashita et al, 1993), and pUC-chimeric E7 were sources of
recombinant pcD2-Y plasmids (pcD2-E7) used in the immortalization
assay in primary BRK cells and in the ras-collaboration assay in primary
REF and BRK cells. Each plasmid was transfected into DH5a and
grown in 500 ml of M9C medium containing 100 mg per ml ampicillin.
Plasmid DNA was puri®ed by the standard SDS/alkaline method
followed by precipitation in 13% PEG6000 solution. The plasmids used
in the yeast two hybrid assay are described below.
Construction of chimeric E7 sequences Chimeric E7 of HPV16 E7
and HPV5 E7 were constructed from pGEM-16E7 and pGEM-5E7
(Yamashita et al, 1993) by using polymerase chain reaction (PCR). The
HPV16 E7 sequences encoding N-terminal 39 amino acid residues (R),
61R and 79R, C-terminal 62R and 37R, the HPV5 E7 N-terminal
41R and 61R, internal 17R, and C-terminal 24R, 42R, and 59R, were
ampli®ed by the primer sets shown in Figs 1 and 2. These fragments
were digested by restriction endonucleases that produced cohesive ends
at the N- or C-terminus of E7 (EcoRI or KpnI) or the blunt end at the
internal site of E7, and were then puri®ed from 1.5% agarose gels.
Recombinant pUC19 carrying chimeric E7 (pUC-E7) was generated by
three-piece ligation of an E7 N-terminus, an E7 C-terminus and pUC19
that was cleaved with EcoRI and KpnI. The chimeric E7 fragments were
then separately subcloned into pGEM3Zf(+) and pcD2-Y. Most parts of
the chimeric E7 sequences in pUC19, including boundaries between
HPV16 and HPV5, were veri®ed by nucleotide sequencing using an
Applied Biosystems model 373S DNA sequencing system (Perkin Elmer,
Urayasu, Japan).
Analysis of chimeric E7 The complementary RNA to HPV16,
HPV5, and their chimeric E7 were synthesized from pGEM-E7 plasmids
by T7 RNA polymerase in vitro and translated in the rabbit reticulocyte
lysate containing 35S-cystein (ICN) as described previously (Yamashita et
al, 1993). The E7 lysates were analyzed by 14% SDS polyacrylamide gel
electrophoresis (SDS/PAGE) and visualized by ¯uorography.
In vitro binding assay Complex formation of HPV E7 and RB was
tested by in vitro mixing experiments (Segawa and Yamaguchi, 1987;
Yamashita et al, 1993). E7 and RB were synthesized by in vitro
transcription and translation as described above. 35S-cystein was
contained in the reaction solution of E7 but not in that of RB. After E7
and RB had been mixed and incubated, coprecipitated E7 was detected
by anti-RB speci®c serum that was detected in the 14% SDS/PAGE
(Yamashita et al, 1993).
Yeast two hybrid assay Cloning of cDNA whose product can bind
C-terminal region of HPV16 E7 was performed by the ``Matchmaker
Two-Hybrid System'' (Clontec Laboratories, Tokyo, Japan). The C-
teminal fragment (40±98R) of HPV16 E7 was fused to the GAL4-DNA
binding domain of pAS2 (pAS-16E7C). HeLa cDNA library fused to the
GAL4 activation domain of pGAD424 was kindly provided from Dr. K.
Yoshida of the Sapporo Medical University. Co-transfection of pAS-
16E7C and HeLa cDNA in pGAD424 into competent yeasts and
screening of candidates were carried out according to the manufacturer's
protocol. Brie¯y, yeast strain HF7c was treated with lithium acetate and
cotransfected with 150 mg of pAS-16E7C and 150 mg of HeLa cDNA-
carrying pGAD424, seeded on the agar plates without tryptophan or
leucine, and cultured at 30°C for a week. The growing colonies were
Figure 2. Locations and sequences of PCR primers used to synthesize E7 fragments. (A) Locations and directions of PCR primers under the
E7 of HPV5 (open arrow) and HPV16 (linear arrow). Nucleotide positions, numbers of amino acid residues (parentheses), and restriction enzymes whose
recognition sequences were tagged to primers are shown under the primers. (B) Primers for N-terminal (16±5¢, 16 N, 16 N¢, 16 N¢¢, 5±5¢, 5 N, and
5 N¢) and C-terminal (16C, 16C¢, 16±3¢, 5C, 5C¢, 5C¢¢, and 5±3¢) fragments of E7 are shown. Underlined nucleotides are restriction sites included in
the primers: EcoRI (16±5¢ and 5±5¢), KpnI (16±3¢ and 5±3¢), EcoRV (16 N), ScaI (16 N¢), HincII (16C¢), BalI (16 N¢¢), DraI (16C), BalI (16 N¢¢),
StuI (5 N), RsaI (5 N¢) HpaI (5C and 5C¢¢), and PmaCI (5C¢). Restriction sites other than EcoRI and KpnI generate blunt ends after cleavage, and six
nucleotides in each primer including three restriction nucleotides were removed from the PCR products. Gothic letters correspond to initiation or
termination codons.
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then screened on the agar without histidine, and ®nally, b-galactosidase-
positive colonies were selected.
RESULTS
Construction of chimeric E7 genes Chimeric E7 were
constructed by PCR (Figs 1, 2) and cloned in the EcoRI and
KpnI site of pUC19 and then subcloned into the pGEM3Zf(+) and
pcD2-Y vectors as described in the Materials and Methods. HPV5
E7, HPV16 E7, and eight different chimeric E7s (Fig 3) were
transcribed in vitro from recombinant pGEM3Zf(+) by T7 RNA
polymerase, and then the complementary RNA were translated
in vitro using the reticulocyte lysate in the presence of 35S-cysteine.
E7 lysates were electrophoresed in 14% SDS/PAGE and E7
polypeptides were visualized by ¯uorography (Fig 4). All of the E7
polypeptides were clearly detected at the position of about 20 kDa
(Fig 4). All the E7 were produced as ef®ciently as parental HPV5
and HPV16 E7 except for 5/16 E7, which is composed of the
HPV5 sequence at the N-terminal 41R and HPV16 at the
C-terminal 62R (Fig 3). The 5/16E7 under the SV40 promoter
(pcD2-5/16E7), however, induced ras-collaborative transformation
with an ef®ciency comparable with HPV5 E7 (pcD2±5E7), as
described below.
Immortalization and transformation by chimeric E7 genes
Primary BRK and REF cells were transfected with one of the
pcD2-E7 plasmids with or without the activated ras gene
(Table II). All of the chimeric E7 produced morphologically
transformed colonies when transfected with the activated ras gene at
an ef®ciency equal to or higher than the transfection of HPV5 E7
plus ras. Ef®cient ras collaboration was observed in REF and BRK
cells transfected with the chimeric E7 containing HPV16 E7 of
N-terminal 39R (16/5E7), 61R (16¢/5E7), and 79R (16¢¢/5E7)
(Table II). This suggests that the N-terminal region of HPV16 E7
is responsible for ef®cient ras-collaborative function. On the other
hand, when primary BRK cells were transfected with each pcD2-
E7 alone, G418-resistant colonies were generated only in the dishes
transfected with pcD2-16¢¢/5E7, which contains N-terminal 79R
of HPV16 E7 (Table II). The G418-resistant colonies from BRK
cells transfected with 16¢¢/5E7 were easily established into cell lines.
These BRK cell lines contained chimeric E7 mRNA detectable by
RT-PCR using the 16±5¢ and 5±3¢ primer set (data not shown).
The result described above suggests that, in addition to the
N-terminal 39 R region that contains the RB-binding domain
(Dyson et al, 1989; Munger et al, 1989b; Davies et al, 1993), the
C-terminal region of HPV16 E7 from 40 through 79 is required for
immortalization of primary BRK cells. In order to test this
possibility, a cotransfection experiment with two chimeric E7 was
carried out (Table III). As a result, immortalized colonies were
generated from dishes transfected with pcD2±16¢/5 E7 plus pcD2±
5¢/16 E7, but not with either of them alone, suggesting that two
separate functions of the N-terminal and C-terminal residues of
HPV16 E7 are required for immortalization of primary BRK cells.
RB-binding experiment It is possible that the strength of RB
binding of E7 determines not only transformation but also
immortalization activity of E7, as immortalizing high-risk HPV16
E7 possesses stronger RB-binding activity than hardly
immortalizing low-risk HPV6/11 and HPV5 E7 (Gage et al,
1990; Munger et al, 1991; Heck et al, 1992; Yamashita et al, 1993).
Complex formation of HPV E7 and RB was tested by in vitro
mixing and coprecipitation experiments. 16/5 E7, 16¢/5 E7, and
16¢¢/5 E7 all showed comparable ras-collaboration activity, but
only 16¢¢/5E7 showed immortalization of primary BRK cells
(Table II). When 16/5E7 and 16¢¢/5E7 were mixed with RB and
precipitated by RB-speci®c antiserum, comparable amounts of
them were recovered (a representative result is shown in Fig 5).
This suggests that function(s) other than RB binding is required for
immortalization activity of HPV E7.
Screening of HeLa cDNA products that bind the HPV16 E7
C-terminal region It is possible that interactions of the
C-terminal region of HPV16 E7 with cellular proteins might be
required for immortalization of primary BRK cells. In order to
isolate cellular proteins that can interact with the C-terminal region
of HPV16 E7, we carried out a yeast two hybrid assay that isolates
HeLa cDNA whose products can bind the C-terminal 40±98R of
HPV16 E7. The plasmid containing the C-teminal 40±98R
fragment of HPV16 E7 fusing to the GAL4-DNA binding
domain and the plasmid containing HeLa cDNA library fusing to
the GAL4 activation domain were cotransfected into competent
yeast HF7c cells. We screened a total of 4.0 3 103 colonies
collected from three transfection experiments, and 11 b-galacto-
Figure 3. Structures of chimeric E7. Each of the E7 subfragments
were synthesized by PCR from pGEM-16E7 or pGEM-5E7 (Yamashita
et al, 1993) and N-terminal (EcoRI site at the 5¢ ends and blunt end at
the 3¢ ends) and C-terminal (blunt end at the 5¢ ends and KpnI site at
the 3¢ ends) fragments were inserted into the EcoRI and KpnI sites of
pUC19. Inserts of recombinant pUC19, HPV5 E7 [open arrow, 103
amino acid residues (R)], HPV16 E7 (linear arrow, 98R) and their
chimeric E7, are shown. Figures on the lines (HPV5 E7) or below the
boxes (HPV16 E7) are the ®rst or last amino acids of each viral E7.
Figure 4. Analysis of chimeric E7 by SDS/PAGE. The chimeric E7
cRNA and their protein products were synthesized from pGEM-E7
plasmids as described in the Materials and Methods. The E7 lysates
(2 3 105 cpm) were analyzed on a 14% SDS/PAGE and visualized by
¯uorography. In each in vitro translation reaction, chimeric E7 products
after incubation for 5, 10, and 20 min were electrophoresed (lanes from
left to right in each E7).
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sidase-positive colonies were selected on the nitrocellulose ®lters.
By a restriction analysis and hybridization experiment, we ®nally
isolated four different cDNA candidates that can bind HPV16 E7
C-terminus in yeast.
DISCUSSION
Viral and cellular factors required for immortalization were
analyzed in primary human cells that are hardly immortalized
spontaneously. Viral oncoproteins are able to immortalize human
cells only when the telomere length is maintained by the
reactivation of telomerase (Klingelhutz et al, 1994; Counter et al,
1994). Recently, a combination of telomerase (hTERT) and
HPV16 E7 (or inactivation of p16INK4a) as well as that of HPV16
E6 and E7 has been reported to induce immortalization of human
cells (Kiyono et al, 1998; McDougall and Klingelhutz, 1999).
Unlike human cells, primary rodent cells, especially primary BRK
cells, are not transferable but can be immortalized by a single
introduction of viral oncogenes. Immortalization of primary BRK
cells is easily detectable by G418 colony-forming assay (Yamashita
et al, 1993, 1999).
We constructed chimeric E7 from immortalizing HPV16 E7 and
nonimmortalizing HPV5 E7 by restriction sequence-tagged PCR
and three piece-ligation methods. Chimeric E7 were synthesized
in vitro in the presence of 35S-cysteine (Fig 4). Unlike HPV5 E7
that showed a single band of approximately 19 kDa, HPV16 E7
always showed two bands of approximately 19 kDa and 22 kDa.
Neither the origin or molecular mechanism of doublet formation of
HPV16 E7 are clear; however, Stoppler et al (1996) reported that
serine protease inhibitors can react with the RB-binding core of
HPV18 E7 to generate an altered form (the lower band) of HPV18
E7. As HPV16 E7 but not HPV5 E7 has as strong an ability to bind
to RB as HPV18 E7, it is possible that the serine protease inhibitors
in the reaction mixture might mediate the production of two forms
of HPV16 E7. It seems that chimeric E7 containing the RB-
binding domain of HPV16 E7 (HPV16 E7, 16/5 E7, 16/5/16 E7,
16¢/5 E7, 16¢¢/5 E7) might be related to the doublet formation
(Fig 4).
Functional analysis of HPV E7 using chimeric E7 to compare
high-risk HPV16 and low-risk HPV6 has been done by several
groups by ras-collaborative transformation assay in primary rodent
cells (Heck et al, 1992; Pater et al, 1992; Takami et al, 1992). Heck
et al (1992) concluded that the transforming activity of E7 resides in
the RB-binding region (15±29R) of HPV16 E7. Similar results
have been reported by other groups (Pater et al, 1992; Takami et al,
1992). In this study, we analyzed a series of chimeric E7 from
immortalizing HPV16 and nonimmortalizing HPV5, and found the
additional novel ®nding that the longer N-terminal region (1±78R)
is required for immortalization of primary BRK cells. It is not likely
that the strength of RB-binding activity of E7 determine the
immortalization activity of E7, as nonimmortalizing 16/5E7 and
immortalizing 16¢/5E7 showed comparable RB-binding activities
(Fig 5). Moreover, when two chimeric E7, 16¢/5 E7 and 5¢/16 E7,
Table II. Immortalization and ras-collaborative transformation of primary rat cells by the chimeric E7a
BRK with ras BRK without ras
DNA REF with ras Exp I Exp II Exp I Exp II
pcD2-Y 0/66 (0%) 0 0 0 0
pcD2-5E7 5/77 (6.6%) 6 2 0 0
pcD2-16E7 32/114 (28.1%) 61 64 20 24
pcD2-5/16E7 5/67 (7.5%) 8 4 0 0
pcD2-16/5E7 26/115 (22.6%) 42 22 0 0
pcD2-16/5/16E7 6/82 (7.3%) 7 6 0 0
pcD2-5¢/16E7 6/75 (8.0%) 6 2 0 0
pcD2-16¢/5E7 25/121 (20.7%) 31 20 0 0
pcD2-16¢¢/5E7 18/110 (16.4%) 46 31 7 8
pcD2-5/16/5E7 11/105 (10.5%) ntb 14 0 0
pcD2-5/16¢/5E7 12/108 (11.1%) nt 2 0 0
aFive3105 of secondary REF or subcon¯uently growing primary BRK cells in 10 cm dishes were transfected with pcD2-E7 alone (20.0 mg) or pcD2-E7 (5.0 mg) plus
pEJ6.6 (15.0 mg), split and cultured in G418-containing media.
bNot tested.
Table III. Colony formation of primary BRK cells by
transfection of two chimeric E7a
DNA
Number of G418-resistant colonies






pcD2-5¢/16E7 + pcD2-16¢/5E7 2 2
aSubcon¯uently growing primary BRK cells in 10 cm dishes were transfected
with 5.0 mg of each plasmid, split and cultured in the G418-medium for 3 wk.
Total DNA per transfection was adjusted to 10.0 mg by adding pcD2-Y.
Figure 5. Detection of RB-binding activity of chimeric E7. HPV5
E7, HPV16 E7, and chimeric E7 with transforming activities, 16/5E7,
16¢/5 E7, and 16¢¢/5 E7, were synthesized in vitro in the presence of 35S-
cysteine. Transforming but not immortalizing 16/5E7 and transforming
and immortalizing 16¢¢/5E7 were separately mixed with in vitro-translated
RB, and E7 peptides associated with RB were precipitated by RB
antiserum and detected by SDS/PAGE.
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were cotransfected, immortalization of primary BRK cells was
induced. Thus, it is suggested that the N-teminal and C-terminal
regions of HPV16 E7 both carry a different function and each of
these functions is responsible for the immortalization of primary
BRK cells.
Recently, a combination of telomerase (hTERT) and HPV16 E7
(or inactivation of p16INK4a) as well as that of HPV16 E6 and E7
has been reported to induce immortalization of human cells
(Kiyono et al, 1998; McDougall and Klingelhutz, 1999); however,
it has not yet been elucidated whether the biochemical function(s)
of mucosal high-risk HPV E7, in addition to the RB binding, is
required for the enhancement of immortalization and the malignant
conversion of HPV-infected human cells. Several cellular proteins
different from RB family members have been reported to interact
with N-terminal and C-terminal regions of E7 (Zwerschke and
Jansen-Durr, 2000). We have found the additional internal region
of HPV16 E7 that is required for immortalization of primary BRK
cells. It is essential to test whether the immortalization-related
function of HPV E7 in the subregion next to the RB-binding
domain (40±79R) can also take place in human cells.
For this purpose, we screened human (HeLa cell) cDNA library
whose products bind the C-teminal 40±98R fragment of HPV16
E7. So far, several cellular proteins have been reported that interact
with the C-terminus of HPV16 E7. These include the transcription
factor AP1 (Antinore et al, 1996), p27Kip1 (Zerfass-Thome et al,
1996), p21Waf1 (Funk et al, 1997; Jones et al, 1997), and the S4
ATPase subunit of the 26S proteasome (Berezutskaya and Bagchi,
1997). Because our cDNA candidates are different from those
reported previously (Yamashita T, Yamano S, Yasuda S, Jin H-Y
and Jimbow K: unpublished data), it will be interesting to test their
complex formation in human keratinocytes and their effect on the
immortalization and transformation of these keratinocytes. The
cDNA we employed were subcloned into an expression vector that
can produce HA-tagged proteins. Interactions between these
cDNA products and HPV16 E7 in the primary human keratino-
cytes are being performed experimentally.
This work was supported in part by Grants-in-Aids for Cancer Research from the
Ministry of Education, Science and Culture of Japan. Most of this work was carried
out in the Department of Molecular Biology, Cancer Research Institute of Sapporo
Medical University. I thank Dr. K. Yoshida and Dr. S. Ishida of the Cancer
Research Institute of Sapporo Medical University for their technical support and
suggestions.
REFERENCES
Antinore MJ, Birrer MJ, Patel D, Nader L, McCance DJ: The human papillomavirus
type16 E7 gene product interacts with and trans±activates the AP1 family of
transcription factors. EMBO J 15:1950±1960, 1996
Arroyo M, Bagchi S, Raychaudhuri P: Association of the human papillomavirus type
16 E7 protein with the S-phase-speci®c E2F-Cyclin A complex. Mol Cell Biol
13:6537±6546, 1993
Barbosa MS, Schlegel R: The E6 and E7 genes of HPV-18 are suf®cient for inducing
two-stage in vitro transformation of human keratinocytes. Oncogene 4:1529±
1532, 1989
Berezutskaya E, Bagchi S: The human papillomavirus E7 oncoprotein functionally
interacts with the S4 subunit of the 26S proteosome. J Biol Chem 272:30135±
30140, 1997
Chen C, Okayama H: High-ef®ciency transformation of mammalian cells by plasmid
DNA. Mol Cell Biol 7:2745±2752, 1987
Choo K-B, Pan C-C: Han S-H. Integration of human papillomavirus type 16 into
cellular DNA of cervical carcinoma: Preferential deletion of the E2 gene and
invariable retention of the long control region and the E6/E7 open reading
frames. Virology 161:259±261, 1987
Counter CM, Botelho FM, Wang P, Harley CB, Bacchetti S: Stabilization of short
telomeres and telomerase activity accompany immortalization of Epstein-Barr
Virus-transformed human B lymphocytes. J Virol 68:3410±3414, 1994
Davies R, Hicks R, Crook T, Morris J, Vousden K: Human papillomavirus type 16,
E7 associates with a histone H1 kinase and with p107 through sequences
necessary for transformation. J Virol 67:2521±2528, 1993
Dyson N, Howley PM, Munger K, Harlow E: The human papillomavirus-16 E7
oncoprotein is able to bind to retinoblastoma gene product. Science 243:934±
937, 1989
van der Eb AJ, Graham FL: Assay of transforming activity of tumor virus DNA. Meth
Enzymol 65:826±839, 1975
Funk J, Waga S, Harry J, Espling E, Stillman B, Galloway D: Inhibition of CDK
activity and PCNA-dependent DNA replication by p21 is blocked by
interaction with the HPV-16 E7 oncoprotein. Genes Dev 11:2090±2100, 1997
Gage JR, Meyers C, Wettstein FO: The E7 proteins of the nononcogenic human
papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in
retinoblastoma protein binding and other properties. J Virol 64:723±730, 1990
Halbert CL, Demers GW, Galloway DA: The E7 gene of human papillomavirus type
16 is suf®cient for immortalization of human epithelial cells. J Virol 65:473±
478, 1991
Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT: HPV16 E6
and E7 proteins cooperate to immortalize human foreskin keratinocytes.
EMBO J 8:3905±3910, 1989
Heck DV, Yee CL, Howley PM, Munger K: Ef®ciency of binding the
retinoblastoma protein correlates with the transforming capacity of the E7
oncoproteins of the human papillomaviruses. Proc Natl Acad Sci USA 89:4442±
4446, 1992
Jewers RJ, Hildebrandt P, Ludlow JW, Kell B, McCance DJ: Regions of human
papillomavirus type 16, E7 oncoprotein required for immortalization of human
keratinocytes. J Virol 66:1329±1335, 1992
Jones DL, Alani RM, Munger K: The human papillomavirus E7 oncoprotein can
uncouple cellular differentiation and proliferation in human keratinocytes by
abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev 11:2101±2111,
1997
Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ: Both
Rb/p16INK4a inactivation and telomerase activity are required to immortalize
human epithelial cells. Nature 396:84±88, 1998
Klingelhutz AJ, Barber SA, Smith PP, Dyer K, McDougall JK: Restration of
telomeres in human papillomavirus-immortalized human anogenital epithelial
cells. Mol Cell Biol 14:961±969, 1994
Klingelhutz AJ, Foster SA, McDougall JK: Telomerase activation by the E6 gene
product of human papillomavirus type 16. Nature 380:79±82, 1996
Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ: Human
papillomavirus infection of the cervix: relative risk associations of 15 common
anogenital types. Obstet Gynecol 79:328±337, 1992
McDougall KJ, Klingelhutz AJ: Telomerase and the HPV oncogenes: More than a
terminal relationship. Papillomavirus Report 10:81±84, 1999
McIntyre MC, Frattini MG, Grossman SR, Laimins LA: Human papillomavirus type
18 E7 protein requires intact Cys-X-X-Cys motifs for zinc binding,
dimerization, and transformation but not for Rb binding. J Virol 67:3142±
3150, 1993
Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R: The E6 and E7
genes of the human papillomavirus type 16 together are necessary and
suf®cient for transformation of primary human keratinocytes. J Virol
63:4417±4421, 1989a
Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM: Complex
formation of human papillomavirus E7 proteins with the retinoblastoma tumor
suppressor gene product. EMBO J 8:4099±4105, 1989b
Munger K, Yee CL, Phelps WC, Pietenpol JE, Moses HL, Howley PM: Biochemical
and biological differences between E7 oncoproteins of the high- and low-risk
human papillomavirus types are determined by amino-terminal sequences. J
Virol 65:3943±3948, 1991
Nevins JR: E2F: a link between the Rb tumor suppressor protein and viral
oncoproteins. Science 258:424±429, 1992
Nishikawa T, Yamashita T, Yamada T, Kobayashi H, Ohkawara A, Fujinaga K:
Tumorigenic transformation of primary rat embryonal ®broblasts by human
papillomavirus type 8 E7 gene in collaboration with the activated H-ras gene.
Jpn J Cancer Res 82:1340±1343, 1991
Orth G: Epidermodysplasia verruciformis. In: Salzman NP, Howley PM, eds. The
Papovaviridae. New York: Plenum, 1987: pp 199±2454
Pater MM, Nakshatri H, Kisaka C, Pater A: The ®rst 124 nucleotides of the E7
coding sequences of HPV16 can render the HPV11 genome transformation
competent. Virology, 1992 186:348±351
Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM: The E6
oncoprotein encoded by human papillomavirus type 16 and 18 promotes the
degradation of p53. Cell 63:1129±1136, 1990
Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, zur
Hausen H: Structure and transcription of human papillomavirus sequences in
cervical carcinoma cells. Nature 314:111±114, 1985
Segawa K, Yamaguchi N: Induction of c-Ha-ras transcription in rat cells by simian
virus 40 large T antigen. Mol Cell Biol 7:556±559, 1987
Shih C, Weinberg RA: Isolation of a transforming sequence from a human bladder
carcinoma cell line. Cell 29:161±169, 1982
Stamps AC, Gusterson BA, O'Hare MJ: Are tumors immortal? Eur J Cancer
28A:1495±1500, 1992
Stoppler H, Stoppler MC, Adduci A, Koval D, Schlegel R: The serine protease
inhibitors TLCK and TPCK react with the RB-binding core of HPV-18 E7
protein and abolish its RB-binding capacity. Virology 217:542±553, 1996
Stoppler H, Hartmann D-P, Sherman L, Schlegel R: The human papillomavirus type
16, E6 and E7 oncoproteins dissociate cellular telomerase activity from the
maintenance of telomerase length. J Biol Chem 272:13332±13337, 1997
Takami Y, Sasagawa T, Sudiro TM, Yutsudo M, Hakura A: Determination of
the functional difference between human papillomavirus type 6 and 16 E7
proteins by their 30 N-terminal amino acid residues. Virology 186:489±495,
1992
74 YAMASHITA ET AL JID SYMPOSIUM PROCEEDINGS
Villa LL: Human papillomavirus and cervical cancer. Adv Cancer Res 114:311±341,
1997
Werness BA, Levine AJ, Howley PM: Association of human papillomavirus type 16
and 18 E6 proteins with p53. Science 248:76±79, 1990
Yamashita T, Segawa K, Fujinaga Y, Nishikawa T, Fujinaga K: Biological and
biochemical activity of E7 genes of the cutaneous human papillomavirus type 5
and 8. Oncogene 8:2433±2441, 1993
Yamashita T, Tonoki H, Nakata D, Yamano S, Segawa K, Moriuchi T: Adenovirus
type 5 E1A immortalizes primary rat cells expressing wild-type p53. Micro
Immunol 43:1037±1044, 1999
Zerfass-Thome K, Zwerschke W, Mannhardt B, Tindle R, Botz J, Jansen-Durr P:
Inactivation of the cdk inhibitor p27Kip1 by the human papillomavirus type16
E7 oncoprotein. Oncogene 13:2323±2330, 1996
Zwerschke W, Jansen-Durr P: Cell transformation by the E7 oncoprotein of human
papillomavirus type 16: interactions with nuclear and cytoplasmic target
proteins. Adv Cancer Res 65:1±29, 2000
VOL. 6, NO. 1 NOVEMBER 2001 IMMORTALIZATION REGION OF HPV16 E7 75
